# Drug of interest
My drug of interest is artemether.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. CYP2B6 (z: 31.52)
2. CYP2C19 (z: 3.36)
3. CYP3A4 (z: 2.79)
4. ABCB1 (z: 2.73)
5. CYP2D6 (z: 2.63)
6. CYP2D7 (z: 2.41)
7. CYP3A5 (z: 2.36)
8. CYP2A7 (z: 2.17)
9. CYP2A6 (z: 1.58)
10. CYP2S1 (z: 1.55)
11. CYP2A13 (z: 1.51)
12. CYP2F1 (z: 1.48)
13. CYP2J2 (z: 1.47)
14. CYP3A7 (z: 0.88)
15. CYP2C18 (z: 0.8)
16. CYP3A43 (z: 0.66)
17. CYP2C8 (z: 0.63)
18. CYP2E1 (z: 0.56)
19. CYP2R1 (z: 0.47)
20. CYP2C9 (z: 0.45)
21. CYP4F2 (z: 0.37)
22. ABCB4 (z: 0.37)
23. CYP1A2 (z: 0.36)
24. G6PD (z: 0.31)
25. CYP4F11 (z: 0.3)
26. CYP4F8 (z: 0.25)
27. CYP4F12 (z: 0.25)
28. CYP4F3 (z: 0.24)
29. POR (z: 0.21)
30. FMO4 (z: 0.21)
31. CYP4X1 (z: 0.2)
32. FMO5 (z: 0.19)
33. CYP4A11 (z: 0.19)
34. ABCC2 (z: 0.17)
35. CYP4B1 (z: 0.17)
36. CYP1B1 (z: 0.17)
37. CYP26C1 (z: 0.16)
38. NR1I2 (z: 0.14)
39. CYP21A2 (z: 0.13)
40. CYP11B2 (z: 0.09)
41. CYP11A1 (z: 0.07)
42. BLVRB (z: 0.06)
43. CYP11B1 (z: 0.05)
44. TBXAS1 (z: 0.05)
45. ADH4 (z: 0.05)
46. COQ8B (z: 0.05)
47. EGLN2 (z: 0.04)
48. ABCB6 (z: 0.02)
49. SYNE2 (z: 0.01)
50. CYP1A1 (z: 0.01)

# Known pharmacogenetic associations
In addition, please consider that the following pharmacogenetic interactions are already known for this drug, according to PharmGKB:
- CYP2B6

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**artemether**: Artemether is metabolized by several cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2B6, CYP2C19, and CYP2C9, into its active metabolite dihydroartemisinin, which is essential for its antimalarial effects. Genetic variations in these enzymes can significantly affect the metabolism of artemether, impacting its efficacy and toxicity, and suggest the importance of tailored dosing based on individual genetic backgrounds to optimize treatment outcomes.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**CYP2B6**: CYP2B6 plays a pivotal role in the metabolism of several drugs, including efavirenz, nevirapine, methadone, bupropion, cyclophosphamide, and ifosfamide, where genetic polymorphisms can significantly influence drug efficacy and safety by altering pharmacokinetic profiles. Genetic variations in CYP2B6 affect the enzyme activity, leading to differences in drug plasma concentrations, therapeutic effects, and potential adverse reactions in individuals, underscoring its importance in personalized medicine.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**CYP2A6**: CYP2A6, an enzyme from the cytochrome P450 superfamily, influences the metabolism of various drugs, impacting their efficacy and toxicity due to genetic variations. It plays a critical role in metabolizing smoking cessation aids like nicotine, cancer treatments such as cyclophosphamide and tegafur, HIV treatment efavirenz, and the glaucoma drug pilocarpine, necessitating dosage adjustments or changes in drug choices to optimize outcomes and minimize side effects.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**CYP3A7**: The CYP3A7 enzyme, important in fetal liver metabolism, interacts with drugs like atorvastatin and tacrolimus by potentially altering their pharmacokinetic profiles and systemic exposure during fetal development due to its activity in metabolizing these CYP3A substrates. Additionally, corticosteroids such as betamethasone and cortisone acetate may also interact with CYP3A7, affecting their metabolic rates and therapeutic outcomes in neonates and infants, though the specific pathway (pharmacokinetic or pharmacodynamic) of these interactions is less defined.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**CYP3A43**: The gene CYP3A43, although not a major player in drug metabolism compared to other enzymes in its subfamily, is known to have specific pharmacokinetic interactions with drugs like olanzapine and ticagrelor, influencing their clearance and plasma concentrations to a minor degree. Its interactions with other antipsychotic drugs such as quetiapine, haloperidol, aripiprazole, risperidone, and clozapine are less defined and are likely related to broader metabolic pathways or pharmacodynamic responses, where CYP3A43 plays a marginal role.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.

**CYP2E1**: The gene CYP2E1 significantly impacts the metabolism of various drugs; for instance, in the case of acetaminophen and isoniazid, variations in CYP2E1 activity can lead to differences in the rate at which these drugs are metabolized, thereby affecting their efficacy, toxicity, and risk of adverse effects such as hepatotoxicity. Additionally, CYP2E1 metabolizes other substances like caffeine, theophylline, nicotine, and some procarcinogens, indicating that genetic variations could influence both therapeutic outcomes and disease risk through pharmacokinetic and possibly pharmacodynamic interactions.

**CYP2R1**: Variations in the CYP2R1 gene can affect the efficiency of vitamin D metabolism by altering the enzyme's ability to convert vitamin D into 25-hydroxyvitamin D, influencing the effectiveness of vitamin D supplementation. Additionally, interactions between CYP2R1 and ribavirin don't involve direct metabolism by the enzyme but may involve indirect effects related to ribavirin’s impact on vitamin D levels or bone health, potentially affecting treatment outcomes in conditions like chronic hepatitis C.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**CYP4F2**: CYP4F2 significantly influences the metabolism of drugs such as vitamin E, vitamin K1, warfarin, and acenocoumarol, affecting their bioavailability and dosing requirements. The enzyme's activity, particularly influenced by the V433M genetic variant, is crucial for the proper breakdown and clearance of these drugs, directly impacting their therapeutic levels and the potential for adverse effects.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**CYP1A2**: CYP1A2 plays a pivotal role in the pharmacokinetics of drugs, influencing their metabolism and, consequently, efficacy and safety. This enzyme is responsible for processing medications such as clozapine, theophylline, caffeine, erlotinib, deferasirox, escitalopram, and clopidogrel, where genetic variability can significantly affect therapeutic outcomes and requires careful dosage adjustments to prevent toxicity or enhance drug effectiveness.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**CYP4F11**: The enzyme CYP4F11 is involved in the metabolism of drugs such as warfarin, aspirin, and erlotinib, influencing their effectiveness and safety by altering degradation rates, plasma levels, therapeutic efficacy, and the profile of side effects. Variations in the activity of CYP4F11 can affect how these drugs are processed in the body, thereby potentially impacting dosage requirements and risk of adverse effects.

**CYP4F8**: CYP4F8 plays a role in the metabolism of fatty acids and leukotriene B4, suggesting that variations in this gene could influence the metabolism and efficacy of dermatological and anti-inflammatory drugs, particularly those like montelukast or zileuton that target leukotriene pathways. The interaction of CYP4F8 with these drugs primarily affects their pharmacokinetics, potentially altering drug effectiveness and safety.

**CYP4F12**: CYP4F12, a cytochrome P450 enzyme, influences the metabolism of drugs that interact with lipid metabolism pathways, including NSAIDs, by affecting processes like hydroxylation of fatty acids. Variants in CYP4F12 could alter the pharmacokinetics of these drugs, potentially impacting their efficacy and safety.

**CYP4F3**: CYP4F3, an enzyme integral to the metabolism of leukotriene B4 and drugs like benzphetamine, influences both the pharmacokinetics and pharmacodynamics of these substances. It modifies the metabolic processing of drugs, potentially affecting their efficacy and side effects, and modulates responses to drugs that act on inflammatory pathways by influencing arachidonic acid metabolism. These interactions could significantly impact therapeutic outcomes, especially in individuals with variant forms of the enzyme.

**POR**: Genetic variations in the POR gene, which is crucial for the function of Cytochrome P450 Oxidoreductase, can significantly affect the pharmacokinetics of drugs such as bupropion, nicotine, tacrolimus, sirolimus, midazolam, voriconazole, and methadone by altering their metabolism and necessitating dose adjustments. While drugs like atorvastatin and sunitinib are also influenced by POR, their interaction is less directly related to its metabolic role, and other drugs such as aspirin and warfarin show complex pharmacodynamic interactions with POR-modulated enzymes rather than straightforward metabolic effects.

**FMO4**: The FMO4 gene encodes for the enzyme flavin-containing monooxygenase 4, which potentially contributes to the metabolism of drugs by affecting their pharmacokinetics, altering plasma drug levels, and impacting therapeutic outcomes or side effects. The exact drugs impacted by FMO4 are still speculative, as FMO4’s interactions with specific drugs are currently not well-documented and remain under research.

**CYP4X1**: CYP4X1, through its role in the hydroxylation of fatty acids, may indirectly influence the pharmacokinetics of lipid-soluble drugs like fluorouracil and cyclophosphamide, potentially affecting their distribution or clearance due to changes in lipid metabolism pathways. Although direct interactions of CYP4X1 with these drugs are not established, its enzymatic activity in fatty acid metabolism suggests possible effects on how these drugs are processed within the body's lipid environments.

**FMO5**: The FMO5 gene, unlike its family members, has a unique role in pharmacogenetics, particularly due to its broad substrate specificity and presence in the liver and small intestine. It indirectly influences drug metabolism, such as with metformin, by potentially altering the metabolic environment or modifying intermediate biomolecules, thus affecting the drug's efficacy and safety through non-traditional pathways related to its handling of metabolic byproducts connected to sulfur and nitrogen.

**CYP4A11**: CYP4A11, a gene involved in fatty acid metabolism, has potential pharmacogenetic implications in hypertension treatment, particularly through indirect interactions with potassium-sparing diuretics like spironolactone and amiloride. These interactions are speculated to involve modulation of hormonal pathways or ion transport mechanisms, rather than direct metabolism by the enzyme, affecting fluid and electrolyte balance critical for blood pressure regulation.

**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**CYP4B1**: CYP4B1, which is involved in the metabolism of fatty acids and xenobiotics, may potentially interact with drugs like docetaxel and thalidomide due to their structural similarities to fatty acids. This interaction could alter the pharmacokinetics of these drugs, affecting their efficacy and safety, although direct evidence of this is currently limited.

**CYP1B1**: CYP1B1 plays a crucial role in the metabolism of a variety of drugs, notably affecting the efficacy and toxicity of oncological treatments such as cyclophosphamide, docetaxel, doxorubicin, epirubicin, paclitaxel, and fluorouracil, and influencing the activation and effectiveness of pain management drugs like codeine and tramadol. Genetic polymorphisms in CYP1B1 can lead to altered enzyme activity, potentially necessitating dosage adjustments to optimize therapeutic outcomes and minimize side effects.

**CYP26C1**: CYP26C1, responsible for retinoic acid metabolism, affects the pharmacokinetics of retinoids like isotretinoin and acitretin, where its genetic variations can alter drug metabolism, influencing their efficacy and safety. Increased CYP26C1 activity might reduce the effectiveness of these drugs by speeding up their metabolism, while decreased activity could increase drug toxicity by allowing higher drug concentrations in the body, suggesting a need for personalized dosing based on CYP26C1 genotype.

**NR1I2**: NR1I2, or pregnane X receptor (PXR), regulates genes encoding drug-metabolizing enzymes and transport systems like CYP3A4 and MDR1, influencing the pharmacokinetics of various drugs. Activators of NR1I2 such as rifampin and carbamazepine can increase the metabolism and decrease the efficacy of drugs like sirolimus and rosuvastatin by upregulating CYP3A4, while inhibitors can slow metabolism, increasing toxicity risk.

**CYP21A2**: The pharmacogenetic interactions of CYP21A2 focus on its role in managing congenital adrenal hyperplasia (CAH), where mutations in this gene affect enzyme activity crucial for steroid biosynthesis. This dictates the use of tailored glucocorticoid therapy, using drugs like hydrocortisone in children and prednisone or dexamethasone in adults, and fludrocortisone for aldosterone deficiency. Treatment adjustments—including the choice and dosage of medication—are essential based on specific CYP21A2 mutations to avoid negative effects such as growth suppression or insufficient control of androgen excess.

**CYP11B2**: CYP11B2, or aldosterone synthase, significantly influences the effectiveness of drugs like spironolactone, candesartan, benazepril, and furosemide by modulating aldosterone synthesis, which subsequently impacts their therapeutic outcomes in managing hypertension and fluid retention. Genetic variations in CYP11B2 can lead to alterations in the pharmacodynamic interactions with these medications, which can vary their efficacy and side effect profiles in treating cardiovascular conditions.

**CYP11A1**: CYP11A1 does not directly affect the metabolism of exogenous drugs but plays a critical role in steroid biosynthesis, impacting the efficacy of drugs like certain corticosteroids and contraceptive pills through variations in endogenous steroid levels. Consequently, alterations in CYP11A1 activity may require dose adjustments in steroid-based therapies, particularly in conditions affecting hormonal balance such as adrenal insufficiency or congenital adrenal hyperplasia (CAH).

**BLVRB**: Drugs that induce hemolysis increase biliverdin levels, thereby intensifying the function of BLVRB in converting biliverdin to bilirubin; variations in the BLVRB gene may affect how patients respond to such drugs, especially given this gene's role in managing bilirubin levels to prevent complications like jaundice. Moreover, drugs that modulate oxidative stress could indirectly influence BLVRB function, thereby affecting its role in maintaining redox homeostasis.

**CYP11B1**: The CYP11B1 gene's role in corticosteroid biosynthesis impacts the pharmacokinetics of drugs like metyrapone, which inhibits CYP11B1 to reduce cortisol production, useful in treating conditions like Cushing's syndrome. Variations in the CYP11B1 gene can affect metyrapone's effectiveness and tolerability by altering enzyme expression or activity, highlighting the importance of considering genetic differences in treatment plans involving corticosteroid imbalances.

**TBXAS1**: Aspirin, an antiplatelet drug, indirectly reduces the activity of TBXAS1, a gene essential for thromboxane A2 production, by inhibiting COX-1 which decreases substrate availability for TBXAS1. Variations in TBXAS1 can therefore affect the drug's efficacy in preventing thrombotic events by altering the responsiveness of thromboxane A2 levels to aspirin therapy.

**ADH4**: The ADH4 gene encodes an enzyme involved in metabolizing alcohol to acetaldehyde, and its genetic variations can affect this process, thereby influencing the efficacy and safety of drugs like disulfiram and naltrexone used in treating alcohol-related conditions. Disulfiram works by increasing acetaldehyde levels to deter alcohol consumption, whereas naltrexone reduces cravings and consumption, both potentially affected by the rate of alcohol metabolism driven by different ADH4 gene variants.

**COQ8B**: The drug CoQ10's effectiveness in treating conditions such as steroid-resistant nephrotic syndrome (SRNS) is influenced by mutations in the gene COQ8B, which is involved in its biosynthesis. CoQ10 supplementation compensates for the deficient production of CoQ10 caused by these mutations, supporting mitochondrial energy production and potentially reducing oxidative stress, thus offering a targeted therapy that aligns with the metabolic and mitochondrial needs dictated by the gene's functional status.

**EGLN2**: Drugs like 3-hydroxycotinine and nicotine interact with the gene EGLN2, which plays a significant role in the cellular response to hypoxia. 3-hydroxycotinine may affect drug metabolism or clearance through its influence on oxygen-sensing pathways moderated by EGLN2, while nicotine can indirectly engage EGLN2 to impact pharmacodynamic responses related to cellular adaptation to low oxygen levels.

**ABCB6**: ABCB6 mutations impact the pharmacokinetics of drugs like cyclophosphamide and doxorubicin by affecting their absorption into cells and intracellular storage, which influences the drugs’ effectiveness and toxicity. This variation in drug handling due to ABCB6 can significantly alter the therapeutic efficacy and side effects of these chemotherapeutic agents, underscoring the importance of genetic considerations in cancer treatment planning.

**SYNE2**: Though SYNE2 does not directly interact with vincristine pharmacokinetically, its association with diseases affecting muscular and cardiac tissues suggests that vincristine's typical pharmacodynamic effects might be altered in individuals with SYNE2 mutations. This alteration could be due to disruptions in nuclear-cytoskeletal connections, affecting vincristine's efficacy and necessitating careful monitoring during its administration in affected patients.

**CYP1A1**: CYP1A1, an important enzyme in drug metabolism, exhibits pharmacogenetic interactions that impact the efficacy and toxicity of drugs like theophylline and clozapine through variations in metabolic activity based on genetic differences. Drugs such as deferasirox, valproic acid, and caffeine among others show altered pharmacokinetics when metabolized by CYP1A1, while others like imatinib and nilotinib might have altered pharmacodynamics or metabolism influenced by CYP1A1 activity, affecting treatment outcomes especially in cancer therapy.
